Allogeneic HCT for Philadelphia chromosome–positive acute lymphoblastic leukemia
| Group (year) . | n . | Median age, y . | Remission status . | Donor . | Conditioning regimen . | OS . | DFS/EFS . | Relapse . | NRM . | Median follow up, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| City of Hope6 (1987) | 10 | 28 (23-45) | CR1; >CR1 | MRD | TBI/VP, TBI/VP/Cy | 60% | 60% | 0% | 40% | 19 |
| CIBMTR19 (1992) | 67 | 28 (5-49) | CR1; >CR1 | MRD | TBI-based Bu/Cy | NR | CR1, 38%; >CR1, 41%; ref, 25% | CR1, 34%; >CR1, 32%; ref, 57% | CR1, 42%; >CR1, 40%; ref, 42% | 36 |
| FHCRC20 (1997) | 18 | 25 (17-51) | CR1; >CR1 | URD | TBI/Cy | NR | 49% | NR | 22% | 17 |
| City of Hope/Stanford7 (1999) | 23 | 30 (6-42) | CR1 | MRD | TBI/VP | NR | All, 65%; < 1992, 45%; > 1992, 81% | 12% | 30% | 40 |
| French LALA21 (2002) | 60 | 42 (17-56) | CR1 | MRD; URD | TBI/VP/CY | 37% | NR | 50% | NR | 54 |
| MRC/ECOG22 (2003) | 87 | < 50 | CR1; >CR1 | MRD; URD | TBI/VP | MRD 42%; URD 36% | MRD 41%; URD 32% | MRD 37%; URD 25% | MRD 35%; URD 57% | NR1 |
| French SGFMTC4 (2003) | 121 | 35 (1-53) | CR1; >CR1 | MRD; URD; UCB | Most TBI/Cy-based | All, 37%; CR1, 50%; >CR1, 17% | NR | All, 44%; CR1, 37%; >CR1, 62% | 36% | 29 |
| Japanese3 (2005) | 197 | 37 (16-59) | CR1; >CR1 | MRD; URD | Most TBI/Cy-based | CR1, 34%; >CR1, 21%; ref, 9% | NR | NR | NR | 58 |
| This study (2008) | 79 | 36 (2-57) | CR1; >CR1 | MRD | TBI/VP; TBI/VP/Cy; TB1/UP/Bu | CR1, 54%; >CR1, 29% | CR1, 48%; >CR1, 26% | CR1, 28%; >CR1, 41% | CR1, 31%; >CR1, 54% | CR1, 75; >CR1, 127 |
| Group (year) . | n . | Median age, y . | Remission status . | Donor . | Conditioning regimen . | OS . | DFS/EFS . | Relapse . | NRM . | Median follow up, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| City of Hope6 (1987) | 10 | 28 (23-45) | CR1; >CR1 | MRD | TBI/VP, TBI/VP/Cy | 60% | 60% | 0% | 40% | 19 |
| CIBMTR19 (1992) | 67 | 28 (5-49) | CR1; >CR1 | MRD | TBI-based Bu/Cy | NR | CR1, 38%; >CR1, 41%; ref, 25% | CR1, 34%; >CR1, 32%; ref, 57% | CR1, 42%; >CR1, 40%; ref, 42% | 36 |
| FHCRC20 (1997) | 18 | 25 (17-51) | CR1; >CR1 | URD | TBI/Cy | NR | 49% | NR | 22% | 17 |
| City of Hope/Stanford7 (1999) | 23 | 30 (6-42) | CR1 | MRD | TBI/VP | NR | All, 65%; < 1992, 45%; > 1992, 81% | 12% | 30% | 40 |
| French LALA21 (2002) | 60 | 42 (17-56) | CR1 | MRD; URD | TBI/VP/CY | 37% | NR | 50% | NR | 54 |
| MRC/ECOG22 (2003) | 87 | < 50 | CR1; >CR1 | MRD; URD | TBI/VP | MRD 42%; URD 36% | MRD 41%; URD 32% | MRD 37%; URD 25% | MRD 35%; URD 57% | NR1 |
| French SGFMTC4 (2003) | 121 | 35 (1-53) | CR1; >CR1 | MRD; URD; UCB | Most TBI/Cy-based | All, 37%; CR1, 50%; >CR1, 17% | NR | All, 44%; CR1, 37%; >CR1, 62% | 36% | 29 |
| Japanese3 (2005) | 197 | 37 (16-59) | CR1; >CR1 | MRD; URD | Most TBI/Cy-based | CR1, 34%; >CR1, 21%; ref, 9% | NR | NR | NR | 58 |
| This study (2008) | 79 | 36 (2-57) | CR1; >CR1 | MRD | TBI/VP; TBI/VP/Cy; TB1/UP/Bu | CR1, 54%; >CR1, 29% | CR1, 48%; >CR1, 26% | CR1, 28%; >CR1, 41% | CR1, 31%; >CR1, 54% | CR1, 75; >CR1, 127 |
OS indicates overall survival; DFS/EFS, disease-free survival/event-free survival; NRM, nonrelapse mortality; CR1, first complete remission; MRD, matched related donor; TBI: total body irradiation; VP, VP16; Cy, cyclophosphamide; mo, months; NR, not reported; ref, refractory; FHCRC, Fred Hutchinson Cancer Research Center; URD, unrelated donor; LALA, Leucemie Aigue Lymphoblastique de l'Adulte; MRC/ECOG, Medical Research Council/Eastern Cooperative Oncology Group; NR1, median follow up not given; survival data reported at 5-year time point; SGFM-TC, Societe Francaise de Greffe de Moelle–Therapie Cellulaire; and UCB, umbilical cord blood.